Sydmarken 11
Søborg
Copenhagen 2860
Denmark
45 88 77 36 00
https://www.zealandpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 355
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Adam Sinding Steensberg M.D. | Pres & CEO | 717.8k | N/A | 1974 |
Mr. Matthew Donald Dallas | Sr. VP & CFO | 578.17k | N/A | 1975 |
Mr. Ivan Mourits Moller | Exec. VP of Technical Devel. & Operations | N/A | N/A | 1972 |
Lani Pollworth Morvan | Investor Relations & Communications Officer | N/A | N/A | N/A |
Mr. Mads Kronborg | Head of Investor Relations & Communication | N/A | N/A | N/A |
Ms. Christina Sonnenborg Bredal | VP of People & Organization | N/A | N/A | 1985 |
Ms. Hanne Heidenheim Bak | Sr. Project Director, R&D Operations Mang. and Employee Representative Director | N/A | N/A | 1953 |
Dr. Jens Damsgaard Mikkelsen M.D. | Head of Molecular Pharmacology | N/A | N/A | N/A |
Dr. Danilo Verge | Head of Global Medical Affairs | N/A | N/A | N/A |
Dr. David M. Kendall M.D. | Sr. Global Medical Advisor of Metabolism | N/A | N/A | 1963 |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Zealand Pharma A/S’s ISS governance QualityScore as of 1 May 2022 is 2. The pillar scores are Audit: 6; Board: 1; Shareholder rights: 1; Compensation: 7.